Omeros stock price target raised to $20 from $9 at H.C. Wainwright

Investing.com - H.C. Wainwright raised its price target on Omeros Corp. (NASDAQ:OMER) to $20.00 from $9.00 on Thursday, while maintaining a Buy rating on the stock. The company’s shares, currently trading at $10.42, have surged over 128% in the past week, according to InvestingPro data.

The price target increase follows Omeros and Novo Nordisk’s announcement of an asset purchase and license agreement for zaltenibart (formerly OMS906), which is in clinical development for rare blood and kidney disorders.

Under the terms of the agreement announced on October 15, Omeros will receive an upfront cash payment of $240 million at closing, with potential for up to $510 million in development and approval milestone payments.

The deal also includes the possibility of up to $1.3 billion in sales-based milestone payments, as well as tiered royalties on annual net sales ranging from high single digits to high teens.

H.C. Wainwright cited the non-dilutive cash Omeros will receive from the transaction and revised risk-adjusted assumptions for zaltenibart’s net present value as key factors driving the price target increase. With analyst targets ranging from $20 to $36, investors can access detailed valuation metrics and 15 additional key insights through InvestingPro’s comprehensive research reports.

In other recent news, Omeros Corporation has announced a significant deal with Novo Nordisk involving its clinical-stage MASP-3 inhibitor, zaltenibart. Under this agreement, Novo Nordisk will gain exclusive global rights to develop and commercialize zaltenibart for all indications. Omeros is set to receive $340 million in upfront and near-term milestone payments, with the potential for total payments to reach $2.1 billion, including development and commercial milestones, along with tiered royalties on net sales. Additionally, Omeros reported its earnings for the second quarter of 2025, revealing a net loss of $0.43 per share, which was better than the forecasted loss of $0.46 per share. Despite beating the earnings expectations, the company’s stock experienced a slight dip in aftermarket trading. The market’s cautious response highlights ongoing concerns regarding Omeros’ path to profitability and regulatory challenges. These developments reflect the company’s strategic moves and financial performance in recent times.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.